<DOC>
	<DOCNO>NCT01222052</DOCNO>
	<brief_summary>In low-risk node-negative breast cancer patient adjuvant chemotherapy spar . The identification subgroup base either clinical pathological tumour-biological criterion . Due high prognostic impact , tumour-biological invasion marker uPA/PAI-1 ( urokinase-type plasminogen activator inhibitor PAI-1 ) potential candidate effectively ass risk relapse node-negative breast cancer . This study aim compare risk assessment traditional clinico-pathological factor tumour-biological factor . The second study question refers comparison adjuvant combination treatment FE100C*6 sequential treatment FE100C*3 Docetaxel*3 .</brief_summary>
	<brief_title>6xFU/Epirubicin/Cyclophosphamide ( FEC ) Compared 3xFEC-3xDocetaxel High-risk Node-negative Breast Cancer Patients</brief_title>
	<detailed_description>1 . To compare FEC*6 FEC*3 follow DOC*3 regard : - primary endpoint study : Disease-Free Survival ( DFS ) - secondary endpoint : Overall Survival ( OS ) , compliance , toxicity chemotherapy patient group 2 . To compare patient low risk accord clinico-pathological versus accord biological risk criterion regard : - proportion low risk versus high risk patient - DFS - OS ( secondary endpoint )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>Histological proven primary breast cancer Tumour size &gt; 0.5 cm &lt; 5 cm ( pT1bpT2 , pN0 , M0 ) Axillary lymph node tumour free ( nodenegative disease ) Adequate surgical procedure : R0resection axillary dissection 10 lymph node examine adequate sentinel procedure qualify centre Frozen tumour tissue available ( analysis biological marker microarrays , centre biological risk assessment ) . The material store liquid nitrogen immediately excision . Paraffin block ( least ) pathology slide primary tumour ( stain unstained ) axillary node ( stain ) available central review . HER2/neu determination immunohistochemistry . Patients stratify HER2/neunegative HER2/neupositive ( HER2/neu Score 3+ , HER2/neu Score 2+ FISH positive ) . No distant metastasis Age &gt; 18 year , &lt; 70 year Performance status ECOG &lt; 2 ( WHO Performance Status 01 ) Adequate cardiac function ( echocardiographically measure leave ventricular ejection fraction ( LVEF ) shorten fraction ( SF ) within normal limit , i.e . ≥55 % ) Adequate bone function ( neutrophil count &gt; 1.5 x109 /l platelet count &gt; 100 x109 /l ) Adequate renal function ( serum creatinine &lt; 120 µmol/l 1.35 mg/dl ) hepatic function ( serum bilirubin &lt; 1 x UNL , ASAT ALAT ( SGOT SGPT ) &lt; 2,5 x UNL ) Before patient registration/randomization , write informed consent must obtain accord ICH/EU GCP , national/local regulation Chemotherapy contraindicate Inflammatory breast cancer , tumour infiltrated axillary lymph node include sentinel node . Other concomitant pathology compromise survival ( entry ) , prevent administration chemotherapy either FEC Docetaxel Other serious illness medical condition may interfere understand give informed consent conduct study Estimated lifeexpectancy &lt; 10 year ( irrespective breast cancer diagnosis ) Patient accessible treatment follow Endocrine treatment accord late standard recommendation AGO Kommission `` Mamma '' Pregnancy , lactation ( sufficient nonhormonal contraception fertile woman require ) Surgery six week ago start chemotherapy Preexisting polyneuropathy Previous concomitant malignancy ( include contralateral breast cancer ) except adequately treat basal squamous cell carcinoma skin situ carcinoma cervix Prior chemotherapy radiotherapy endocrine therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>high risk breast cancer</keyword>
	<keyword>low risk breast cancer</keyword>
	<keyword>uPA</keyword>
	<keyword>urokinase-type plasminogen activator</keyword>
	<keyword>PAI</keyword>
	<keyword>plasminogen activator inhibitor-type</keyword>
</DOC>